We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Judge Paves Way for Sandoz’s Newly Approved Neupogen Biosimilar
Judge Paves Way for Sandoz’s Newly Approved Neupogen Biosimilar
Nothing is stopping Sandoz from launching the first U.S. biosimilar, now that a federal judge has denied Amgen’s bid for an injunction blocking the alternate version of its blockbuster chemotherapy product Neupogen.